Biora Therapeutics, Inc. (BIOR)
Market Cap | 36.76M |
Revenue (ttm) | 726,000 |
Net Income (ttm) | -117.31M |
Shares Out | 9.10M |
EPS (ttm) | -14.50 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 495,361 |
Open | 3.94 |
Previous Close | 3.92 |
Day's Range | 3.86 - 4.30 |
52-Week Range | 1.95 - 52.75 |
Beta | 1.06 |
Analysts | Buy |
Price Target | 84.15 (+1,977.78%) |
Earnings Date | Mar 27, 2023 |
About BIOR
Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract a... [Read more]
Financial Performance
In 2021, BIOR's revenue was $1.25 million, an increase of 669.75% compared to the previous year's $162,000. Losses were -$247.41 million, 28.3% more than in 2020.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for BIOR stock is "Buy." The 12-month stock price forecast is $84.15, which is an increase of 1,977.78% from the latest price.
News

Biora Therapeutics, Inc. (BIOR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Biora Therapeutics, Inc. (BIOR), indicating that the stock has found support. This, combined with an upward trend in earnings...

Biora Therapeutics Presents Data from Device Performance Study with Repeat Doses in Both Fasted and Fed States at Crohn's & Colitis Congress
Study demonstrates targeted delivery devices functioned as designed when administered with food, potentially enabling non-fasted administration Study demonstrates targeted delivery devices functioned ...

Why Is Biora Therapeutics (BIOR) Stock Up 12% Today?
Biora Therapeutics (NASDAQ: BIOR) stock is on the rise Wednesday following news of feedback from the FDA. Today's news concerns the company's Targeted Therapeutics Platform and PGN-600 program for th...

Biora Therapeutics Receives Pre-IND Feedback from FDA and Provides Update on Key Programs for 2023
Company is on track to move into the clinic with its lead targeted therapeutics program Company is on track to move into the clinic with its lead targeted therapeutics program

Biora Therapeutics Announces Reverse Stock Split
SAN DIEGO, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will effect a reverse stock split...

Biora Therapeutics Announces Two Poster Presentations at the Crohn's & Colitis Congress
SAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced acceptance of two abstracts presenti...

Biora Therapeutics Licenses Preeclampsia Rule-Out Test for Commercial Development
Avero Diagnostics to Develop and Commercialize, Enabling Potential Future Revenue for Biora Therapeutics Avero Diagnostics to Develop and Commercialize, Enabling Potential Future Revenue for Biora The...

Biora Therapeutics, Inc. (BIOR) Reports Q3 Loss, Misses Revenue Estimates
Biora Therapeutics, Inc. (BIOR) delivered earnings and revenue surprises of -33.33% and 20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the st...

Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Presented results of human study at the American College of Gastroenterology annual meeting, demonstrating promising device performance in active ulcerative colitis patients

Biora Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update
SAN DIEGO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report third quarter en...

Biora Therapeutics Announces $9.75 Million Direct Offering
SAN DIEGO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has entered into a definitiv...

Biora Therapeutics Announces Sale of Cell-Free DNA Patent Rights
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it has completed a one-time asset sa...

Biora Therapeutics Shares Data from Device Performance Study in Ulcerative Colitis Patients
Data Presented at the ACG Annual Meeting Demonstrates Successful Detection of Colon Entry and Topical Coverage Throughout Portion of Colon Implicated in Patients with Active Ulcerative Colitis Data Pr...

Biora Therapeutics Shares Five Posters Presented at American College of Gastroenterology Annual Scientific Meeting 2022
Presents Results on Device Performance Studies in Humans for Targeted Therapeutics Platform Presents Results on Device Performance Studies in Humans for Targeted Therapeutics Platform

Biora Therapeutics Shares Preclinical Data on Oral Delivery of Biologics at the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference
Further Demonstrating Possibilities for Systemic Delivery of Large Molecules Further Demonstrating Possibilities for Systemic Delivery of Large Molecules

Biora Therapeutics to Participate in 12th Annual Partnership Opportunities in Drug Delivery Conference
SAN DIEGO, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, announced today that the company will participate in the 12t...

Biora Therapeutics Announces Issuance of Key Patent for Oral Delivery of GLP-1 Receptor Agonists
Patent Covers Jet Delivery of GLP-1 Receptor Agonists to the Small Intestine for Treatment of Any Disease Including Type 2 Diabetes Patent Covers Jet Delivery of GLP-1 Receptor Agonists to the Small I...

Biora Therapeutics Appoints Dr. Bruce Sands as Chair of its Clinical Advisory Board
SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, announced today the appointment of Dr. Bruce Sands as board...

Biora Therapeutics to Participate in Upcoming H.C. Wainwright Investment Conference
SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced that the company's management team will be ...

Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Successfully completed PM-602 human study for its targeted therapeutics platform demonstrating promising device performance in active ulcerative colitis patients

Biora Therapeutics Announces Successful Completion of Device Performance Study in Ulcerative Colitis Patients for its Targeted Therapeutics Platform
All Devices Successfully Detected Colon Entry in Patients with Active Ulcerative Colitis All Devices Successfully Detected Colon Entry in Patients with Active Ulcerative Colitis

Biora Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update
SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced that it will report second quarter ended Jun...

Biora Therapeutics Announces Five Abstracts Accepted at American College of Gastroenterology Annual Scientific Meeting 2022
SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced the acceptance of five abstracts for present...

Biora Therapeutics to Participate in Upcoming BTIG Investment Conference
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced that the company's management team will be p...

Biora Therapeutics Shares Preclinical Data on Oral Delivery of Biologics at Controlled Release Society 2022
Demonstrates OBDS Device Performance and Bioavailability in Animal Models Demonstrates OBDS Device Performance and Bioavailability in Animal Models